The Boston, USA-based unit of French nuclear medicines firm Curium today announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against ...
Curium™ is pleased to announce that it has prevailed in the patent dispute brought by Novartis subsidiary Advanced Accelerator Applications against Curium™ concerning Curium’s Lutetium Lu 177 dotatate ...
The recapitalization will accelerate Curium's strategy to launch innovative, life-changing diagnostic and therapeutic solutions for cancer patients around the world BOSTON, Nov. 20, 2025 (GLOBE ...
Curium’s strategic investment of over €32 million will establish a European production line for 177 Lu-PSMA-I&T, a therapeutic agent for patients with metastatic castration-resistant prostate cancer ...
PARIS, March 28, 2025 (GLOBE NEWSWIRE) -- Curium Pharma (“Curium”), a world leader in nuclear medicine, is pleased to announce the completion of its acquisition of Eczacıbaşı-Monrol Nuclear Products ...
NEW YORK & LONDON--(BUSINESS WIRE)--Annaly Capital Management, Inc. (NYSE:NLY) (“Annaly” or the “Company”) and Curium Data Systems (“Curium”) today jointly announced that Annaly has successfully ...
Actinides are a group of heavy, radioactive elements that include uranium, plutonium, americium, curium, berkelium and californium. Understanding how these elements bond with other atoms (known as ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results